Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
FORMULA-509 trial: what clinicians have said so far
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
- NCT03141671 ↗
- Unknown
- Dana-Farber Cancer Institute
- Deep size, estimated: 301+ verified statements
We haven't built an HCP commentary report on FORMULA-509 (abiraterone plus apalutamide in prostate cancer with rising PSA after radical prostatectomy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on FORMULA-509 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 58 posts on X | |
| 15 podcast episodes | |
| 8 YouTube videos |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Prostate Cancer
- Interventions
- GnRH; Bicalutamide; Salvage radiation; Abiraterone; Prednisone; Apalutamide
- Arms
- GnRH + Bicalutamide · Experimental
- GnRH+Abiraterone+Apalutamide+Prednisone · Experimental
- Enrollment
- 345
- Primary outcomes
- PSA Progression Free Survival
- Sponsor
- Dana-Farber Cancer Institute with Janssen Pharmaceutica
- Start
- Nov 24, 2017
- Primary completion
- Apr 5, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT03141671 · updated May 14, 2024